Metformin may cut mortality risk in post-pancreatitis diabetes

Metformin may cut mortality risk in post-pancreatitis diabetes

(HealthDay)—Metformin use may promote a survival benefit in individuals with post-pancreatitis diabetes mellitus (PPDM), but not pancreatic cancer-related diabetes (PCRD), according to a study published online June 21 in Diabetes Care.

Jaelim Cho, M.D., M.P.H., from the University of Auckland in New Zealand, and colleagues used nationwide pharmaceutical dispensing data (from 2006 to 2015) linked to to identify 1,862 individuals with PCRD or PPDM.

The researchers found that in individuals with PCRD, ever users of (adjusted hazard ratio [aHR], 0.54) and ever users of insulin (aHR, 0.46) had significantly lower risks of mortality versus patients never using antidiabetic medications. However, these associations were weakened with the use of a 6-month lag. In individuals with PPDM, compared with never users of antidiabetic medications, ever users of metformin had a significantly lower risk of mortality (aHR, 0.51; 95 percent confidence interval [CI], 0.36 to 0.70), whereas ever users of insulin did not have a significantly changed risk of mortality (aHR, 0.75; 95 percent CI, 0.49 to 1.14). Even with a 6-month lag, the association between metformin use and mortality risk remained significant.

"Reverse causality may play a role in the association between insulin use and in PCRD," write the authors.

More information: Abstract/Full Text (subscription or payment may be required)

Journal information: Diabetes Care

Copyright © 2019 HealthDay. All rights reserved.

Citation: Metformin may cut mortality risk in post-pancreatitis diabetes (2019, July 2) retrieved 2 October 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Metformin may reduce cancer mortality risk


Feedback to editors